Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $2,072,208.85 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the sale, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Insmed Stock Performance

Shares of Insmed stock opened at $72.87 on Thursday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The stock has a market capitalization of $10.83 billion, a price-to-earnings ratio of -13.93 and a beta of 1.11. The firm has a fifty day moving average of $74.77 and a two-hundred day moving average of $51.39.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the company earned ($1.78) EPS. The company’s revenue was up 17.0% compared to the same quarter last year. As a group, equities research analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research analyst reports. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. TD Cowen raised their target price on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Thursday, August 29th. Finally, Guggenheim upped their target price on shares of Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.

Institutional Trading of Insmed

Hedge funds have recently modified their holdings of the company. EntryPoint Capital LLC acquired a new position in Insmed during the first quarter valued at approximately $33,000. Fidelis Capital Partners LLC acquired a new position in shares of Insmed in the 1st quarter valued at $34,000. First Horizon Advisors Inc. increased its position in shares of Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Insmed in the 1st quarter valued at $59,000. Finally, CWM LLC raised its stake in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.